Oliver Sartor, MD



Academic Office – (504) 988-7869
Clinic Appointments – (504) 988-7869
Email: osartor@tulane.edu


Dr. Oliver Sartor is the only medical oncologist in Louisiana specializing in the treatment of prostate cancer patients. Dr. Sartor, the Laborde Professor of Cancer Research in the Medicine and Urology Departments of Tulane School of Medicine, helps to complete the world-class prostate cancer team at the Tulane Cancer Center. Together, Lee, Sartor and Thomas are overseeing the prostate cancer program that offers state-of-the-art clinical and surgical care. Before joining Tulane’s faculty, Sartor was an associate professor in the Lank Genitourinary Oncology Center at Harvard’s Dana-Farber Cancer Institute in Boston. He is also chair-elect of the Department of Defense Prostate Cancer Integration Panel, which directs over $70 million in federal funding for prostate cancer research.

Sartor was previously at the Louisiana State University Health Sciences Center in New Orleans, where he was the director of the Stanley S. Scott Cancer Center. He was also co-director of the Louisiana Cancer Research Consortium, a legislatively established tobacco tax funded public-private partnership focused on enhancing cancer research in Louisiana.
Sartor has a clinical and scientific interest in advanced prostate cancer. Specifically, his research has focused on novel therapies for prostate cancer.

Prior to his return to New Orleans, Dr. Sartor was an associate professor of medicine at Harvard Medical School.

Sartor is the editor-in-chief of the peer-reviewed journal Clinical Genitourinary Cancer and the author of more than 100 scientific papers. He received his medical degree from Tulane University, and completed a fellowship with the National Cancer Institute. He is a member of several professional societies, including the American Society of Clinical Oncology, the American Association for Cancer Research, the American Urological Association, and the Society of Urologic Oncology, and board certified in internal medicine and medical oncology.